web analytics
13.3 C
Munich
Sunday, August 1, 2021

Enzolytics, Inc. (ENZC) Running Hard As Co Partners With Intel to Publish White Paper on AI Artificial Intelligence Targeting Monoclonal Antibodies

Enzolytics, Inc. (ENZC) is making a powerful move up the charts in recent days since a brief dip below the $0.10 mark. ENZC is a major league runner and powerhouse stock; over the past few months ENZC has seen a legendary run to recent highs of 0.958 per share as it completes the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19. With each day of progression of the Coronavirus pandemic, the dire need for multiple active therapeutics becomes more evident. ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. A break over $0.958 and its blue skies ahead for ENZC.

ENZC has partnered with Intel to publish a white paper titled, “Optimizing Empathetic A.I. to Cure Deadly Diseases,” highlighting Intel’s Artificial Intelligence Analytic tools and Enzolytic’s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants. This collaborative effort approaches the future of medicine; a future wherein the process of healthcare evolves from reactive to anticipatory, as exemplified by P4 Medicine. The conclusion described in the White Paper is that Enzolytics Inc’s use of Artificial Intelligence underscores a novel approach in assessing millions of virus sequences to identify the conserved segments essential for virus survival. Through effective public and private sector symbiosis and the fostering of a technology-neutral regulatory environment, the genuine power of A.I., coupled with advanced techniques in proprietary technologies illustrated in the Enzolytics immunotherapeutics, will no doubt create universal, durable, and broadly effective treatment targeting all virus variants. This was followed by the news that ENZC has identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). Utilizing the Company’s proprietary Artificial Intelligence (AI) methodology, conserved target sites have now been identified against which fully human anti-HTLV-1 monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University’s Institute for Preclinical Studies. The Company’s own Artificial Intelligence team continues to identify the critical sites on viruses against which monoclonal antibodies will be produced to treat infectious viral diseases.

Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. ENZC has been rapidly building up an intellectual property portfolio filing numerous patents last year. Most recently, last month, the Company reported it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for “Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor – Pharmaceutical Composition for Treatment.”  Since than the ENZC has filed a number of new applications. The Company recently merged with BioClonetics Immunotherapeutics, Inc., now a wholly owned subsidiary of Enzolytics; a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases. 

Microcapdaily has been reporting on the ENZC BioColnetics merger since the beginning recenlty stating: “Enzolytics Inc. ENZC: is making a highly explosive move up the charts recently surpassing $0.50 per share and regularly topping $25 million USD per day in dollar volume ENZC has transformed into a major league runner in small caps. Enzolytics and its new subsidiary BioClonetics own licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS a market expected to be worth $30 billion plus by 2025. The Company produces targeted (nontoxic) monoclonal antibodies and is now advancing two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirusEnzolytics has attracted a major league level management team behind it and has expanded its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it is producing both addition monoclonal antibodies against HIV and the against covid-19. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Microcapdaily first reported on ENZC the day after the merger was announced in our article: “BioClonetics LOI Sparks Enzolytics Inc (OTCMKTS: ENZC)” on September 16 when ENZC was trading for well under $0.01  

Enzolytics has quickly attracted a power house team behind it which speaks of big things to come here. They recently appointed Ronald Moss, M.D., to the Medical Advisory Board. Mr. Moss has been an executive with numerous biotech’s over the past 25 years. He has extensive clinical and regulatory management expertise in guiding programs through Phase I, II, and III clinical trials, including IND and NDA experience. The Company’s Chief Science Officer, Mr. Henry Zhabilov has managed several clinical trials utilizing therapeutic proteins. He is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company’s IPF platform. 

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
ENZC

May has been a big month for ENZC; On May 12 Enzolytics announced it has granted a distributorship license to a European pharma entity (the Licensing Entity) for the right to distribute the Company’s anti-HIV-1 therapeutic ITV-1 in the countries of India, Pakistan, UAE, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda, North Sudan, Egypt, Morocco, and Tunisia (the Licensed Territory). The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will received $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million. The License is granted with a commitment by the Licensee to sale and distribute the ITV-1 therapeutic in the Licensed Territory. In addition, the Licensing Entity will invest $2 Million USD in the Company in exchange for Company Preferred Series E stock bringing to the Company $3 Million in cash plus a 50% ownership in the Licensing Entity. 

The deal comes as a result of Enzolytic management developing and strengthening the relationships that are now leading the Company to its current significant partnerships. With the advances Enzolytic is making toward preparation for and completion of clinical trials in Europe, which will lead to approval from the EMA, the Company is meeting its goal of bringing its technology to those in need. 

The Company also partnered with Intel to publish a white paper on May 17 titled, “Optimizing Empathetic A.I. to Cure Deadly Diseases, highlighting Intel’s Artificial Intelligence Analytic tools and Enzolytic’s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants. This collaborative effort approaches the future of medicine; a future wherein the process of healthcare evolves from reactive to anticipatory, as exemplified by P4 Medicine, a term coined by Biologist Leroy Hood: 

The White Paper underscores Intel’s recognition of the premise of P4 Medicine and embraces Artificial Intelligence to deliver on the promise. Intel has made incredible advances in Artificial Intelligence’s applications to Empathetic A.I., outsourcing healthcare tasks and decisions to rational machines, freeing up time for healthcare professionals to engage in empathetic care, cultivating trusting relationships with their patients. 

Intel commends the discovery of Dr. Joseph Cotropia and Dr.Gaurav Chandra. Dr. Cotropia discovered a genetic amino acid sequence designated KLIC in the outer envelope of HIV. Discovering this sequence is like finding a “needle in a haystack” and retrieving the needle. These immutable sites have been identified and the antibody that targets those sites created. This antibody (Clone 3) can lock onto the KLIC epitope. Once bound by the antibody, the virus cannot infect a human cell and cannot ultimately reproduce. 

Patented by Dr. Cotropia, this HIV monoclonal antibody has been successfully tested in five international labs. Clone 3 antibody neutralized [at an IC90] 95% of all HIV primary isolate strains (41/43) -across all clades and groups – against which tested it. For an antibody to be effective, it has to attack a neutralizable site on the virus that is always present and does not mutate. Knowing the binding site for the monoclonal Clone 3 antibody on the HIV-1 virus and then examining the Coronavirus amino acid sequence, a correlation in the structures has been identified by Dr. Joseph Cotropia and Dr. Gaurav Chandra. Specific antibodies that broadly neutralize are necessary to provide effective therapy and prevention of disease. These applications in using a monoclonal antibody in passive immunotherapy are accomplished by using Enzolytics’ proprietary method of producing broadly neutralizing monoclonal antibodies. However, a primary focus on identifying immutable binding sites on the virus and then creating monoclonal antibodies that bind to such immutable sites is required will universally and durably neutralize the SARS-CoV-2 virus. Dr. Gaurav Chandra recognized A.I.’s potential and, based on knowledge of these homologous viral structures, targeting the corresponding “Achilles Heel” site on a virus, an expected conserved immutable and neutralizable site was identified. 

Consequently, Dr. Chandra worked with Denver Scientific’s genetics molecular biology data science team to screen more than 50,512 Coronavirus and 87,336 HIV isolates, the largest known repository of HIV and Covid- 19 isolates in the world. From this very complex and extensive A.I. analysis, conserved sites immutable on HIV and Covid-19 were identified. The use of A.I. helped to confirm the sequence determined throughout two decades of Dr. Cotropia’s career. Additionally, another seven conserved sequences have also been identified using A.I. technology, while in another breakthrough, 19 conserved sequences over the entirety of the 50,512 Coronavirus isolates analyzed have been identified. These immutable sites on the SARS-CoV-2 virus have also been confirmed as existing (100%) in the U.S. SARS-CoV-2 virus variants that have surfaced in United Kingdom, Brazil, and South Africa. 

As a trifecta, Intel technology, P4 Medicine, and the efforts of Enzoyltics requires effective public policy; policies that will fuel this trifecta as a promising thought leadership experiment; a necessary journey of experimentation as humanity bravely marches towards cures for society’s most deadly diseases; towards a more Empathetic A.I. Cultivating a technology-neutral public policy, regulatory, and government investment environment is paramount to this end. The consensus is for five primary policy drivers to cultivate trust, empathy, and velocity that will help in realizing the potential described in the White Paper. The five policy drivers are to: 

The conclusion described in the White Paper is that Enzolytics Inc’s use of Artificial Intelligence underscores a novel approach in assessing millions of virus sequences to identify the conserved segments essential for virus survival. Through effective public and private sector symbiosis and the fostering of a technology-neutral regulatory environment, the genuine power of A.I., coupled with advanced techniques in proprietary technologies illustrated in the Enzolytics immunotherapeutics, will no doubt create universal, durable, and broadly effective treatment targeting all virus variants. 

On May 26 ENZC announced it has identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus. Utilizing the Company’s proprietary Artificial Intelligence (AI) methodology, conserved target sites have now been identified against which fully human anti-HTLV-1 monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University’s Institute for Preclinical Studies. The Company’s own Artificial Intelligence team continues to identify the critical sites on viruses against which monoclonal antibodies will be produced to treat infectious viral diseases. Experts recognize the significance of producing multiple monoclonal antibodies targeting multiple conserved sites as a necessary approach to effective therapy. This allows the administration of a “cocktail” of antibodies, all targeting conserved and expectedly immutable sites. 

Charles Cotropia, CEO of Enzolytics, said: “We now have a comprehensive platform for producing multiple targeted monoclonal antibodies against numerous infectious diseases. This platform includes our ability to first identify multiple conserved and expectedly immutable sites on viruses with the ability to then produce fully human monoclonal antibodies targeting those sites. This approach opens the door to new and durable therapies that can be used to treat innumerable human infectious diseases.” 

https://twitter.com/HeavyCryptoBag/status/1400853300673540101

For more on ENZC Subscribe Right Now!

Enzolytics is making a powerful move up the charts in recent days since a brief dip below the $0.10 mark. ENZC is a major league runner and powerhouse stock; over the past few months ENZC has seen a legendary run to recent highs of 0.958 per share as it completes the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19. With each day of progression of the Coronavirus pandemic, the dire need for multiple active therapeutics becomes more evident. ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. ENZC has partnered with Intel to publish a white paper titled, “Optimizing Empathetic A.I. to Cure Deadly Diseases,” highlighting Intel’s Artificial Intelligence Analytic tools and Enzolytic’s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants. This collaborative effort approaches the future of medicine; a future wherein the process of healthcare evolves from reactive to anticipatory, as exemplified by P4 Medicine. The conclusion described in the White Paper is that Enzolytics Inc’s use of Artificial Intelligence underscores a novel approach in assessing millions of virus sequences to identify the conserved segments essential for virus survival. Through effective public and private sector symbiosis and the fostering of a technology-neutral regulatory environment, the genuine power of A.I., coupled with advanced techniques in proprietary technologies illustrated in the Enzolytics immunotherapeutics, will no doubt create universal, durable, and broadly effective treatment targeting all virus variants. This was followed by the news that ENZC has identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). Utilizing the Company’s proprietary Artificial Intelligence (AI) methodology, conserved target sites have now been identified against which fully human anti-HTLV-1 monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University’s Institute for Preclinical Studies. The Company’s own Artificial Intelligence team continues to identify the critical sites on viruses against which monoclonal antibodies will be produced to treat infectious viral diseases. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

More articles

1 COMMENT

  1. My daughter was diagnosed with Epilepsy. The neurologist was very confident about the diagnosis based, my Daughter had an EEG (no idea if it showed anything; we were tired and may have misunderstood what he said about that). MRI was negative for problems. For the past 4 months or so, I have seen weekly occurrences, making strange faces (this involved cheek twitching and lip quivering). We did not realize it could be a serious problem until she had an obvious seizure (simple partial) last week. What is troubling about my daughter condition is that we have seen many daytime seizures, and that recently the seizures seem to cluster together. No idea if there are seizures occurring at night. We were given a prescription for Kapra, but are still weighing the risk / rewards of giving the medication to a toddler. After returning from the hospital, my daughter experienced a round a vomiting lasting from 3 AM to 11 AM, followed by additional vomiting the following morning at around 2 AM. Nothing sense then. She has not had an appetite, is drinking fine, and otherwise appears healthy. I read a lot of blogs where people who shared their testimonies kept mentioning Anti-seizure Herbal medication. I searched for a website I just followed the email address of Doctor Patrick that was shared on these testimonies; I got lucky when I got a reply from Dr. Patrick. I followed his instruction, used Herbal Medicine in less than 2 months, my daughter seizures reduced drastically. Within a period of 5 months, my daughter was cured. I went back to my neurologist, where my daughter checked up and marked epilepsy free. If you need his help you can Contact this herbal doctor via his email herbalmedicalhome@gmail.com and WhatsApp connection is +2348021312463 https://www.facebook.com/doctorakhidenor for help…
    He has cure to all this following also
    1. Ischaemic heart disease
    2. Cerebrovascular disease
    3. Lower respiratory infections
    4. Chronic obstructive pulmonary disease
    5. Diarrhoeal diseases
    6. HIV/Aids
    7. Trachea, bronchus, lung cancers
    8. Tuberculosis, Diabetes v
    9. Necrotising fasciitis
    10.Stoke
    11.Cholera
    12.Pneumonic plague
    13.Ebola
    14.Dengue haemorrhagic fever
    Contact this herbal doctor via his email herbalmedicalhome@gmail.com and WhatsApp connection is +2348021312463 https://www.facebook.com/doctorakhidenor for help.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.